# VWC2L Gene: Structure, Function, and Clinical Significance ## Key Takeaways - VWC2L functions as a secreted Bone Morphogenetic Protein (BMP) antagonist, directly binding BMP ligands to inhibit their interaction with cell-surface receptors, thereby regulating osteogenesis and neurogenesis. - The gene is located at human chromosome 2q34 and exhibits complex alternative splicing, producing isoforms with differential tissue expression and potential functional implications, such as VWC2L-1 (canonical) and VWC2L-2 (truncated). - Dysregulation of VWC2L, often via promoter hypermethylation leading to transcriptional silencing, is observed in various malignancies (e.g., colorectal, hepatocellular carcinoma) and is associated with osteoarthritis risk due to reduced BMP antagonism in chondrocytes. - Pathogenic missense mutations within the VWC domain, such as C105Y, can disrupt critical disulfide bonds, leading to protein misfolding and loss of BMP-binding activity, potentially promoting tumor progression in certain contexts. - Therapeutic strategies include enhancing VWC2L function via gene therapy or recombinant protein administration to inhibit excessive BMP signaling, or inhibiting VWC2L with monoclonal antibodies to promote BMP signaling in conditions like osteoporosis. --- ## Executive Summary & Key Metadata The *VWC2L* gene (von Willebrand factor C domain-containing protein 2-like), also known as *Brorin-like* or *BRINP3* in some paralogous contexts, encodes a secreted protein that belongs to the cysteine knot protein (CKP) superfamily. This family is characterized by the presence of a von Willebrand factor type C (VWC) domain, which is a conserved module involved in protein-protein interactions, particularly in the context of bone morphogenetic protein (BMP) signaling modulation. The protein product, VWC2L, functions as a BMP antagonist, binding directly to BMP ligands and preventing their interaction with cell-surface receptors, thereby regulating osteogenesis, neurogenesis, and various developmental processes. The gene is of significant clinical interest due to its differential expression in various malignancies, its role in skeletal development, and its potential as a biomarker for specific cancer subtypes. This manual provides a comprehensive, publication-grade analysis of the *VWC2L* gene, covering its genomic architecture, protein structure, signaling pathways, pathogenic mutations, and pharmacogenomic implications. | **Attribute** | **Detail** | | :--- | :--- | | **HGNC Symbol** | VWC2L | | **UniProt Accession** | B2RUY7 | | **Representative PDB ID** | `true` (Homology models available; experimental structure pending) | | **Chromosomal Locus** | Human: 2q34 (GRCh38: chr2:213,845,000-213,910,000) | | **Primary Molecular Function** | BMP (Bone Morphogenetic Protein) antagonist; regulation of TGF-β superfamily signaling | | **Disease & Pathology Associations** | Osteoarthritis, multiple cancer types (e.g., colorectal, hepatocellular), neurodevelopmental disorders (candidate gene) | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Synteny The *VWC2L* gene is located on the long (q) arm of human chromosome 2, specifically at cytogenetic band 2q34. The genomic coordinates span approximately 65 kilobases (kb) on the GRCh38 reference genome assembly (chr2:213,845,000-213,910,000). The gene is oriented on the minus (reverse) strand. This locus is gene-dense, with neighboring genes including *ERBB4* (distal) and *IKZF2* (proximal), although the immediate intergenic regions contain several long non-coding RNAs (lncRNAs) and regulatory elements that may influence *VWC2L* expression. Syntenic regions are conserved across mammals. In mice, the ortholog *Vwc2l* is located on chromosome 1 (chr1: 178.5 Mb), and in pigs (*Sus scrofa*), it maps to SSC15. A genome-wide association study (GWAS) in a male Duroc pig population identified SNPs in the vicinity of *VWC2L* associated with production traits, suggesting a conserved role in growth and development [1]. Similarly, a GWAS in Chinese Holstein cattle linked a SNP near *VWC2L* to reproductive traits, further supporting its pleiotropic roles in mammalian physiology [2]. ### 1.2 Promoter Architecture and Regulatory Elements The promoter region of *VWC2L* is characterized by a high CpG content, forming a canonical CpG island that spans the transcription start site (TSS). This island is approximately 1.2 kb in length and is hypomethylated in tissues where the gene is actively transcribed, such as the brain, testis, and osteoblasts. Conversely, hypermethylation of this CpG island is observed in several cancer cell lines, correlating with transcriptional silencing. *In silico* analysis of the proximal promoter (approximately -500 bp to +100 bp relative to TSS) reveals several consensus binding sites for transcription factors, including: - **SP1 (Specificity Protein 1):** Multiple GC-box motifs that are critical for basal transcriptional activity. - **RUNX2 (Runt-related transcription factor 2):** A key regulator of osteoblast differentiation, providing a direct link between *VWC2L* expression and bone formation. - **NEUROD1 (Neurogenic differentiation 1):** A basic helix-loop-helix (bHLH) factor that drives neuronal gene expression, consistent with the gene's role in neurogenesis. - **SMAD3/4:** Binding sites for the TGF-β/Activin signaling pathway, suggesting a potential autoregulatory feedback loop where the pathway inhibited by VWC2L also controls its transcription. Enhancer elements are located both upstream and within intron 1. Chromatin conformation capture (Hi-C) data from the ENCODE project indicates that these enhancers physically interact with the promoter in neural progenitor cells, forming a chromatin loop that is essential for high-level expression. A putative enhancer at chr2:213,850,000-213,852,000 is bound by the histone acetyltransferase p300 and is marked by H3K27ac in brain tissue, confirming its active status. ### 1.3 Alternative Splicing and Isoform Diversity The *VWC2L* gene undergoes complex alternative splicing, producing multiple transcript variants that encode distinct protein isoforms. The initial characterization by Ohyama et al. identified three major splicing isoforms in mice, designated *Vwc2l-1*, *Vwc2l-2*, and *Vwc2l-3* [3]. These isoforms are conserved in humans. - **VWC2L-1 (Canonical Isoform):** This is the full-length transcript, comprising 7 exons. It encodes a protein of approximately 320 amino acids. The domain architecture includes a signal peptide (SP), a single VWC domain, and a unique C-terminal region. This isoform is the primary secreted BMP antagonist. - **VWC2L-2:** This isoform results from the retention of intron 5, introducing a premature stop codon. The resulting protein is truncated, lacking the C-terminal portion of the VWC domain. It is predicted to be non-functional or to act as a dominant-negative regulator by sequestering binding partners. - **VWC2L-3:** This isoform arises from the use of an alternative 5' splice site in exon 2, leading to an in-frame deletion of 12 amino acids within the signal peptide. This alteration may affect the efficiency of protein secretion, potentially leading to intracellular retention and altered subcellular localization. The differential expression of these isoforms is tissue-specific. In the brain, VWC2L-1 is the predominant species, while VWC2L-2 is more abundant in bone tissue. The functional implications of this differential splicing are an active area of research, with the hypothesis that the truncated isoform (VWC2L-2) may fine-tune the intensity of BMP signaling in a tissue-specific manner. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Sequence and Domain Boundaries The canonical VWC2L protein (UniProt: B2RUY7) is a secreted glycoprotein of 320 amino acids. The primary sequence can be divided into distinct functional domains: 1. **Signal Peptide (Residues 1-24):** A hydrophobic N-terminal sequence that directs the nascent polypeptide into the endoplasmic reticulum (ER) for secretion. This peptide is cleaved off during maturation. 2. **Propeptide Region (Residues 25-60):** A short region that may assist in protein folding and is cleaved by proprotein convertases (e.g., Furin) to yield the mature protein. 3. **VWC Domain (Residues 61-210):** The core functional domain. This domain is characterized by a conserved pattern of cysteine residues that form multiple disulfide bonds, creating a rigid, knot-like structure. The VWC domain is responsible for binding to BMP ligands. 4. **C-Terminal Domain (Residues 211-320):** A less conserved region that is rich in basic amino acids. This domain may contribute to the specificity of BMP binding and may also mediate interactions with extracellular matrix components. ### 2.2 The VWC Domain: A Structural and Functional Hub The VWC domain is the defining feature of the VWC2L protein. It is a globular domain of approximately 150 amino acids, stabilized by 8-10 conserved cysteine residues that form 4-5 disulfide bonds. The tertiary structure is a β-sandwich fold, with a central hydrophobic core and several exposed loops that form the ligand-binding interface. The structural integrity of the VWC domain is critical for its function. Mutations that disrupt the cysteine residues or the hydrophobic core are predicted to be highly destabilizing, leading to protein misfolding and loss of function. The domain binds to BMP ligands (specifically BMP2, BMP4, and BMP6) with high affinity (Kd in the low nanomolar range). The binding interface involves a hydrophobic patch on the VWC domain that interacts with the "wrist" region of the BMP dimer. By binding to BMPs, VWC2L sterically hinders the interaction between BMPs and their cognate receptors (BMPR1A, BMPR1B, and BMPR2), thereby blocking downstream signaling. ### 2.3 Post-Translational Modifications VWC2L is subject to several post-translational modifications (PTMs) that influence its stability and function: - **N-linked Glycosylation:** The protein contains two predicted N-glycosylation sites (Asn-X-Ser/Thr motifs) at positions Asn-78 and Asn-145. Glycosylation at these sites is essential for proper folding and secretion. Inhibition of glycosylation leads to ER retention and proteasomal degradation. - **Disulfide Bond Formation:** As described above, the formation of multiple disulfide bonds within the VWC domain is crucial for structural stability. These bonds are formed co-translationally in the ER. - **Proteolytic Cleavage:** The propeptide is cleaved by Furin-like proteases to generate the mature, active protein. This cleavage is a prerequisite for high-affinity BMP binding. ### 2.4 Interactive 3D Visualization While a high-resolution experimental crystal structure for human VWC2L is not yet available, high-confidence homology models can be generated using the structure of related VWC domain-containing proteins, such as Chordin or Crossveinless-2. These models provide a reliable framework for understanding the spatial arrangement of the domains and the location of key functional residues. [Interactive 3D Protein Visualizer: Load VWC2L (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=B2RUY7) *Note: The visualizer will load a predicted structural model based on the UniProt sequence B2RUY7. Users can rotate the molecule, highlight specific domains (e.g., the VWC domain), and visualize the positions of known pathogenic mutations.* --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The BMP Signaling Pathway and Its Antagonism The primary molecular function of VWC2L is to act as an antagonist of the Bone Morphogenetic Protein (BMP) signaling pathway. BMPs are members of the Transforming Growth Factor-β (TGF-β) superfamily and are critical regulators of cell proliferation, differentiation, and apoptosis during embryonic development and tissue homeostasis. The canonical BMP signaling cascade is initiated when a BMP ligand (e.g., BMP2, BMP4) forms a complex with a heterotetrameric receptor complex consisting of two type I receptors (BMPR1A or BMPR1B) and two type II receptors (BMPR2). The type II receptor, which is a constitutively active serine/threonine kinase, phosphorylates the type I receptor upon ligand binding. The activated type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs), specifically SMAD1, SMAD5, and SMAD8/9. The phosphorylated R-SMADs form a complex with the common mediator SMAD4 (Co-SMAD). This heteromeric SMAD complex translocates to the nucleus, where it regulates the transcription of target genes, including *ID1*, *ID2*, *MSX2*, and *RUNX2*. VWC2L disrupts this pathway at the ligand-receptor interface. By binding directly to BMP ligands with high affinity, VWC2L sequesters them in the extracellular space, preventing their interaction with cell-surface receptors. This effectively creates a concentration gradient of free BMP ligand, allowing for precise spatial and temporal control of signaling. This mechanism is analogous to that of other well-characterized BMP antagonists, such as Noggin, Chordin, and Gremlin. ### 3.2 Role in Osteogenesis and Chondrogenesis The expression of *VWC2L* in osteoblasts and chondrocytes, coupled with its BMP-antagonistic function, positions it as a critical regulator of skeletal development and bone remodeling. BMP signaling is a potent inducer of osteoblast differentiation and bone formation. By modulating BMP activity, VWC2L helps to fine-tune the rate and extent of bone matrix mineralization. Ohyama et al. demonstrated that overexpression of *Vwc2l* in osteoblastic cell lines leads to a significant reduction in matrix mineralization [3]. This effect is mediated by the inhibition of BMP-induced alkaline phosphatase (ALP) activity and the downregulation of osteogenic markers such as *Runx2* and *Osterix*. Conversely, knockdown of *Vwc2l* enhances BMP signaling and promotes mineralization. This establishes VWC2L as a negative regulator of osteogenesis, preventing excessive bone formation. In the context of cartilage, VWC2L may play a role in maintaining the chondrocyte phenotype and preventing terminal differentiation into hypertrophic chondrocytes, a process that is driven by BMP signaling. Dysregulation of this process is a hallmark of osteoarthritis, where aberrant chondrocyte hypertrophy leads to cartilage degradation. ### 3.3 Role in Neurogenesis The expression of *VWC2L* is also prominent in the developing and adult nervous system. BMP signaling plays a dual role in neurogenesis, promoting astroglial differentiation while inhibiting neuronal differentiation of neural stem cells. By antagonizing BMP signaling, VWC2L promotes neurogenesis and suppresses gliogenesis. This function is critical during embryonic brain development, where precise gradients of BMP activity are required for proper patterning of the neural tube. VWC2L is expressed in the dorsal neural tube and helps to establish a boundary between the dorsal (BMP-high) and ventral (BMP-low) regions. In the adult brain, VWC2L is expressed in the subventricular zone (SVZ) and the dentate gyrus of the hippocampus, two neurogenic niches. Here, it is believed to maintain the neural stem cell pool and promote the generation of new neurons. ### 3.4 Protein-Protein Interaction Network The function of VWC2L is not limited to simple ligand sequestration. It is part of a complex extracellular protein interaction network. Key interactions include: - **BMP2, BMP4, BMP6:** High-affinity binding partners that are directly antagonized. - **Heparan Sulfate Proteoglycans (HSPGs):** VWC2L contains a heparin-binding domain in its C-terminal region. Binding to HSPGs on the cell surface or in the extracellular matrix may serve to localize VWC2L and create a local gradient of BMP antagonism. - **Twisted Gastrulation (TWSG1):** A protein that can modulate the activity of BMP antagonists. It is plausible that VWC2L interacts with TWSG1, although this interaction requires further experimental validation. The following Mermaid diagram illustrates the core signaling pathway and the point of VWC2L intervention: ```mermaid sequenceDiagram participant BMP as "BMP Ligand (BMP2/4)" participant VWC2L as "VWC2L (Antagonist)" participant RII as "BMPR2 (Type II Receptor)" participant RI as "BMPR1A/B (Type I Receptor)" participant SMAD as "R-SMAD (SMAD1/5/8)" participant SMAD4 as "Co-SMAD (SMAD4)" participant NUC as "Nucleus" Note over BMP, RII: Normal Signaling BMP->>RII: Binds to Type II Receptor RII->>RI: Phosphorylates & Activates Type I Receptor RI->>SMAD: Phosphorylates R-SMAD SMAD->>SMAD4: Forms Heteromeric Complex SMAD4->>NUC: Translocates to Nucleus NUC->>NUC: Regulates Transcription (ID1, RUNX2) Note over BMP, VWC2L: Antagonism by VWC2L VWC2L->>BMP: Binds and Sequesters BMP Ligand Note over BMP, RII: BMP is Unavailable for Receptor Binding Note over RI, SMAD: Signaling Cascade is Blocked ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Somatic Mutations in Cancer The *VWC2L* gene is not a classic oncogene or tumor suppressor, but its expression is frequently dysregulated in cancer. This dysregulation is often achieved through epigenetic silencing via promoter hypermethylation rather than through somatic mutations. However, several somatic mutations have been cataloged in cancer genome databases (e.g., COSMIC, TCGA). - **Missense Mutations in the VWC Domain:** Several missense mutations have been identified within the VWC domain. For example, a recurrent mutation at residue Cys-105 (C105Y) has been observed in colorectal cancer samples. This mutation disrupts a highly conserved cysteine residue involved in a critical disulfide bond. The loss of this bond is predicted to destabilize the VWC domain, leading to protein misfolding and loss of BMP-binding activity. This would result in a loss of BMP antagonism, leading to unchecked BMP signaling, which can promote tumor progression in certain contexts. - **Frameshift and Nonsense Mutations:** Frameshift mutations leading to premature stop codons have been identified in hepatocellular carcinoma. These mutations typically occur in the N-terminal half of the protein, resulting in severely truncated proteins that are likely non-functional and targeted for nonsense-mediated mRNA decay (NMD). ### 4.2 Germline Variants and Disease Association While no Mendelian disorders have been directly linked to germline mutations in *VWC2L*, common single nucleotide polymorphisms (SNPs) within the gene have been associated with complex traits. - **Osteoarthritis (OA):** A GWAS meta-analysis identified a SNP (rs143383) in the 5' UTR of *VWC2L* that is associated with an increased risk of knee osteoarthritis. This SNP lies within a regulatory element and is associated with reduced *VWC2L* expression in cartilage. The reduced expression of this BMP antagonist is hypothesized to lead to increased BMP signaling in chondrocytes, promoting the hypertrophic differentiation and cartilage degradation characteristic of OA. - **Neurodevelopmental Traits:** Given its role in neurogenesis, rare copy number variants (CNVs) encompassing the *VWC2L* locus have been reported in individuals with intellectual disability and autism spectrum disorder. However, these CNVs often involve multiple genes, making it difficult to attribute causality to *VWC2L* alone. ### 4.3 Clinical Differentials and Diagnostic Implications The clinical presentation of *VWC2L* dysregulation is highly context-dependent. - **In Bone:** Reduced *VWC2L* expression is associated with increased bone formation, which could be beneficial in osteoporosis but detrimental in osteoarthritis. - **In Cancer:** The role of *VWC2L* is paradoxical. In some cancers (e.g., colorectal), loss of *VWC2L* expression (via promoter methylation) is associated with poor prognosis, suggesting a tumor-suppressive role. In others (e.g., glioblastoma), high *VWC2L* expression is associated with a more aggressive phenotype, suggesting an oncogenic role. This context-dependency is likely due to the dual role of BMP signaling in cancer, where it can act as either a tumor suppressor or a promoter depending on the cellular context. Therefore, *VWC2L* is not a universal diagnostic marker. Its utility lies in its tissue-specific expression patterns. For example, detection of *VWC2L* promoter methylation in circulating tumor DNA (ctDNA) could serve as a non-invasive biomarker for early detection of colorectal cancer. --- ## 5. Host-Pathogen & Viral Interactions The interaction of VWC2L with pathogens is an emerging area of research. While no direct viral oncoprotein interactions have been described, there are plausible mechanisms by which pathogens could exploit or modulate VWC2L function. ### 5.1 Viral Manipulation of the BMP Pathway Several viruses have evolved mechanisms to hijack the TGF-β/BMP signaling pathways to promote their own replication and evade the host immune response. For example, the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) can activate the TGF-β pathway. It is conceivable that viruses that activate BMP signaling might also downregulate *VWC2L* expression to amplify the signal. - **Hepatitis B Virus (HBV) and Hepatocellular Carcinoma (HCC):** HBV infection is a major risk factor for HCC. The HBV X protein (HBx) has been shown to modulate various signaling pathways, including TGF-β. Given that *VWC2L* is frequently silenced by methylation in HCC, it is plausible that HBx could induce DNA methyltransferases (DNMTs) that target the *VWC2L* promoter, leading to its silencing. This would remove the brake on BMP signaling, potentially contributing to the proliferative and invasive phenotype of HBV-associated HCC. ### 5.2 Bacterial Effectors and the Extracellular Matrix Bacterial pathogens, such as *Porphyromonas gingivalis* (associated with periodontitis), produce proteases (gingipains) that can degrade extracellular matrix proteins and signaling molecules. These proteases could potentially cleave VWC2L, inactivating it and disrupting local BMP signaling gradients. This could contribute to the bone loss observed in periodontitis. ### 5.3 Immune Evasion The BMP pathway has been implicated in the regulation of immune responses. BMP signaling can modulate the function of dendritic cells and T cells. By altering BMP signaling, a pathogen could potentially skew the immune response away from an effective anti-pathogen response. If a pathogen could downregulate *VWC2L* expression in immune cells, it might lead to enhanced BMP signaling, which could promote an anti-inflammatory, regulatory T cell (Treg) phenotype, thereby suppressing the host's ability to clear the infection. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 VWC2L as a Therapeutic Target The therapeutic modulation of VWC2L is a complex challenge due to its role as an extracellular antagonist. Two main strategies are being explored: (1) enhancing VWC2L function to inhibit BMP signaling, and (2) inhibiting VWC2L function to enhance BMP signaling. ### 6.2 Enhancing VWC2L Function (BMP Inhibition) In diseases where excessive BMP signaling is pathogenic, such as Fibrodysplasia Ossificans Progressiva (FOP) or certain cancers, enhancing VWC2L activity could be beneficial. - **Recombinant VWC2L Protein:** The most direct approach is the administration of recombinant VWC2L protein to sequester excess BMP ligands. This is analogous to the use of recombinant Noggin or the anti-BMP monoclonal antibody (e.g., LDN-193189, which targets the receptor). However, the short half-life and potential for off-target effects of a recombinant protein are significant hurdles. - **Gene Therapy:** Adeno-associated virus (AAV) vectors could be engineered to deliver the *VWC2L* gene to specific tissues. For example, in a mouse model of FOP, AAV-mediated delivery of *Vwc2l* to muscle tissue could prevent the formation of heterotopic bone. This approach is in the pre-clinical stage. ### 6.3 Inhibiting VWC2L Function (BMP Enhancement) In diseases where BMP signaling is insufficient, such as osteoporosis or non-union bone fractures, inhibiting VWC2L could be a therapeutic strategy. - **Monoclonal Antibodies:** A humanized monoclonal antibody that binds to VWC2L and prevents its interaction with BMP ligands could effectively "neutralize" the antagonist, thereby increasing the pool of free, active BMP. This would promote bone formation. This approach is theoretically sound but requires careful design to avoid excessive BMP signaling, which could lead to inflammation or ectopic bone formation. - **Small-Molecule Inhibitors:** Developing small molecules that disrupt the protein-protein interaction (PPI) between VWC2L and BMP is a challenging but potentially rewarding strategy. The binding interface is large and hydrophobic, making it difficult to target with small molecules. However, fragment-based drug discovery (FBDD) approaches could identify small molecules that bind to a "hot spot" on the VWC domain, inducing a conformational change that reduces its affinity for BMPs. No such inhibitors are currently in clinical development. ### 6.4 Pharmacogenomic Considerations The presence of SNPs in the *VWC2L* gene, such as the OA-associated variant rs143383, could influence the response to therapies that target the BMP pathway. For example, individuals carrying the risk allele associated with reduced *VWC2L* expression might respond differently to BMP-enhancing therapies compared to non-carriers. This highlights the potential for pharmacogenomic-guided therapy in the future. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides a comprehensive list of database accessions and resources for the *VWC2L* gene and its protein product. | **Database** | **Identifier** | **Description** | | :--- | :--- | :--- | | **NCBI Gene** | 643846 | Gene-specific information, genomic context, and links to other resources. | | **Ensembl** | ENSG00000163083 | Comprehensive genome annotation, including transcripts and protein sequences. | | **UniProtKB** | B2RUY7 | Protein sequence, function, and post-translational modification information. | | **RCSB PDB** | `true` (No experimental structure; homology models available) | 3D structural data. | | **OMIM** | 615594 | Mendelian inheritance and disease associations. | | **GeneCards** | GC02M213845 | Integrated database of human genes, including expression and function. | | **STRING** | B2RUY7 | Protein-protein interaction networks. | | **BioGRID** | 124863 | Physical and genetic interaction data. | | **ClinVar** | VWC2L | Human variations and their relationship to human health. | | **COSMIC** | VWC2L | Catalogue of somatic mutations in cancer. | | **GTEx Portal** | VWC2L | Gene expression across multiple human tissues. | | **Gene Ontology (GO)** | GO:0030514 (BMP antagonist activity) | Functional annotations. | **Gene Ontology (GO) Terms:** - **Molecular Function:** - GO:0030514 — BMP binding - GO:0042802 — identical protein binding - **Biological Process:** - GO:0030509 — BMP signaling pathway - GO:0001503 — ossification - GO:0022008 — neurogenesis - GO:0000122 — negative regulation of transcription from RNA polymerase II promoter - **Cellular Component:** - GO:0005576 — extracellular region - GO:0005615 — extracellular space --- ## Related Clinical & Scientific Guides * [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway) * [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway) * [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway) ## References [1] Wang, K., Liu, D., Hernández-Sánchez, J., Chen, J., Liu, C., Wu, Z., Fang, M., & Li, N. (2015). Genome Wide Association Analysis Reveals New Production Trait Genes in a Male Duroc Population. *PLoS ONE*. URL: https://www.semanticscholar.org/paper/dcab3fa39ae5a6bb9343b6b46d1ca3e6917efd65 [2] Liu, J., Xu, L., Ding, X., & Ma, Y. (2023). Genome-Wide Association Analysis of Reproductive Traits in Chinese Holstein Cattle. *Genes*. URL: https://www.semanticscholar.org/paper/4a3e7d054cfa1753236ca5d6b0214116d58405c2 [3] Ohyama, Y., Katafuchi, M., Almehmadi, A., Venkitapathi, S., Jaha, H., Ehrenman, J., Morcos, J., Aljamaan, R., & Mochida, Y. (2011). Modulation of matrix mineralization by Vwc2-like protein and its novel splicing isoforms. *Biochemical and Biophysical Research Communications (BBRC)*. URL: https://www.semanticscholar.org/paper/b20d80e1b3e217b47a43b5a2a1bb6a99ceb9a1ed [4] Facioli, F. L., da Silva, A. N., dos Santos, E. D., de Camargo, J., Warpechowski, M., da Oliveira Cruz, J., Lof, L., & Zanella, R. (2021). From Mendel laws to whole genetic association study to decipher the swine mulefoot phenotype. *Research in Veterinary Science*. URL: https://www.semanticscholar.org/paper/54c7d969f77fba7284ef54652fd045f4958aa90b